Latest news
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
New phase 3 findings presented at ADA 2026 suggest the next wave of cardiometabolic therapies is moving beyond blood sugar control and weight loss, towards broader effects on liver fat, cardiovascular risk markers, sleep apnoea and obesity-related complications.
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
AI in Cardiology Moves From Promise to Policy Pressure
Europe’s Safe Hearts Plan Makes Prevention a Political Test
AI Diabetes Tools Need Infrastructure Before Scale
Diabetes Tech Moves From Optional Add-On to Earlier Care
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.